Dechra Veterinary Products has added to its Veterinary Essentials range of veterinary-licensed post-patent products with the launch of Fiprocat and Fiprodog, a fipronil spot-on solution for the treatment and prevention of on-animal flea infestations in cats and dogs.
Available in packs of 3 or 6 pipettes, Fiprocat and Fiprodog are only distributed through the veterinary channel. Dechra highlights the product's convenient self-standing pipette. which it says makes the process of applying the spot-on easier.
Dechra says it offers a wealth of client support material, and practice promotional support to go with the product.
Fiprocat and Fiprodog can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).
Rob Simpson at Dechra said: "Fipronil has been used in the treatment and prevention of on-animal flea infestations for many years and is one of the most commonly used treatments in practice. Fiprocat and Fiprodog join R.I.P Fleas Extra to offer a cost effective complete flea solution to tackle both on-animal and environmental flea infestations."
The Small Animal Medicine Society (SAMSOC) and the BSAVA have together produced a new poster containing guidelines for the appropriate use of antibiotics in practice.
In recent years, alongside wider recognition of resistant bacteria such as MRSA in animals, the veterinary profession's use of antibiotics has been under the spotlight as a possible factor contributing to the increasing prevalence of bacterial resistance seen in human patients. Veterinary surgeons are faced with the dual problem of treating more and more resistant bacterial infections, whilst the threat of withdrawal of the right to prescribe certain antibiotics hangs over the profession.
SAMSoc and the BSAVA say they feel the time has come for the veterinary profession to take a coordinated responsible approach to its prescribing practices.
Ian Battersby of the Small Animal Medicine Society (SAMSoc) has sought to address the need for rational guidelines for the most appropriate antibiotics, for the correct duration, to maximise clinical efficacy but minimise selection of resistant bacteria. Collaboration with BSAVA resulted in a set of helpful prescribing guidelines in poster form, being sent to members of both associations. A limited number of copies will also be available from the BSAVA Balcony at Congress 2012, and BSAVA has dedicated the October issue of its membership magazine, companion, to the subject.
Ian said: "Of course these PROTECT guidelines are suggestions based on current knowledge and in the future we hope they will be further refined as our experience grows. This is an evolving situation and hopefully more work will be undertaken, in particular looking at treatment durations, allowing further refinement and optimization of practice policies. The key principles are that by implementing a prescribing protocol in our practices we are treating our prescribing privileges responsibly and maximizing the efficacy of the presently available agents for the benefit of both veterinary and human patients now and in the future.
"I would like to particularly thank everyone who has helped with this project; Andrew Jagoe, Professor Ian Ramsey, Tom Maddox, Jon Camillari, Alison Woodward and Dr Tim Nuttall, and BSAVA for facilitating the production of the poster".
Anne is originally from New York City and obtained her veterinary degree from Purdue University in 2011.
She completed her rotating internship at Louisiana State University, followed by two research fellowships at Michigan State University and Nihon University.
She then completed her residency at the RVC, before achieving diplomate status of the American College of Veterinary Internal Medicine (Cardiology) in 2017.
Anne's interests include treatment and management of congestive heart failure, feline cardiomyopathy and cardiac interventions.
She said: “I’m delighted to be joining the cardiology team at DWR at a very exciting time, supporting the recently-launched open-heart surgery service.
“We’re one of very few hospitals in the world to be able to offer this treatment, so being a part of this is a great challenge, both personally and professionally.”
For more information visit www.dickwhitereferrals.com
Open to all veterinary professionals looking to enhance their knowledge and skills in emergency and critical care, this year's Congress has a lineup of over 30 internationally-renowned speakers and leading clinicians and offers up to 70 hours of CPD.
This year’s keynote speaker is specialist transplant nurse and chair of the UK One Health Coordination Group, Helen Ballantyne, and organisers will also be welcoming veterinary nurse Ken Yagi, formerly program director of the CPR simulation lab at Cornell University, who’ll deliver an update on the new RECOVER (CPR) guidelines being released this year.
Simon Hagley, ECC Specialist and Clinical Director at Vets Now hospital in Manchester said: “We are confident our 2024 programme offers something for everyone, no matter what stage of your ECC career you are at, from students through to specialists and everything in between.
"We listened to delegate feedback from last year’s event, and we have brought back some firm favourites including our ’Controversies’ and ‘Joined Up Thinking sessions’, but we have introduced exciting new streams including 'Catastrophic case conversations'.
“We’ve also we’ve extended the popular nursing streams from last year to span two entire days and lunchtime case presentations from interns across the country are also on the programme.”
https://www.vets-now.com/congress
The RCVS is reminding veterinary surgeons and nurses that there is one week left till the deadline for nominations for the 2012 RCVS and RCVS VN Council elections.
Nominations must be made in writing on the prescribed form and received by the RCVS on or before 31 January 2012.
Prospective candidates need to provide the signatures and registered/listed addresses of two proposers, and should also submit a short biography, manifesto and photograph for inclusion in the RCVS News Extra election specials.
Nobody may nominate more than one candidate, and no current member of the RCVS Council or VN Council may make a nomination.
Full details and guidance notes for both elections are available online from the RCVS Council Election page (www.rcvs.org.uk/rcvscouncil12) and VN Council Election page (www.rcvs.org.uk/vncouncil12).
Nomination forms and candidate information forms for RCVS Council may also be requested from Mrs Gabriella Braun (020 7202 0761 or executiveoffice@rcvs.org.uk) and those for VN Council from Mrs Annette Amato (020 7202 0713 or a.amato@rcvs.org.uk).
Six seats on RCVS Council and two on VN Council are due to be filled in the 2012 elections.
Those elected will take their seats on RCVS Day in July, to serve four-year terms, and will be expected to spend at least six to eight days a year attending Council meetings, working parties and subcommittees (a loss-of-earnings allowance is available).
Woodley Equipment has expanded its support team with the appointment of Greg Woloszczuk as the new Wet Chemistry Product Support Specialist.
Greg joins Woodley from the veterinary industry where he worked for 5 ½ years as a Service Manager. He will focus on all areas of customer service, pre and post sales, along with organising servicing, repairs and maintenance of the Woodley wet chemistry analysers.
The range includes a spray, collars and diffusers.
Unlike many other pheromone diffusers which need to be plugged into a wall socket, Virbac's uses a patent-pending slow release technology which doesn't need power.
Virbac says the new range has been scientifically proven with published studies which demonstrate not only their effectiveness in managing stress-related behaviours in dogs and cats, but also an equivalent and superior efficacy to the current market leading pheromone products 1,2,3
Andrew Connolly, Virbac's Marketing Director for the UK and Ireland said: "Veterinary professionals have a crucial role to play in supporting their clients with the behavioural management of their pets, both when visiting the practice and at home, and the benefits of pheromones in helping to manage dog and cat behaviour are already very well recognised."
"With Zenidog and Zenifel we hope to make pheromone therapy easier, more cost-effective and better for the environment."
Zenidog and Zenifel are available to order from NVS, Covetrus and VSSCo now.
References
Open to all in the veterinary profession, the event offers up to ten hours of CPD, and covers a range of topics such as orthopaedics, ECC, medicine, wellbeing, and education.
There will also be practical sessions to attend on both days on transfusions, CPR, and physio.
Speakers include:
There's a commercial exhibition, and social events including the Ceilidh at the annual BSAVA PetSavers Gala Dinner on Friday evening.
Prices start at £85 +VAT for a day pass, with early bird rates offered to both BSAVA members and non-members until 27th July.
Additional discounts are available when sending the whole practice team.
https://www.bsavaevents.com/bsavaalba23/en/page/home
Horiba says subclinical hypocalcaemia (SCH) is a significant and under-diagnosed metabolic problem in dairy cattle affecting up to 50% cows annually.
After lactation, total calcium levels in the cows’ blood drop which can lead to sub-optimal health and yield.
The webinar will be presented by James Husband BA, VetMB, DipECBHM, DCHP, MRCVS, who will offer the benefit of his research and experience on the subject.
At the end, there'll be a Q&A session.
During the webinar, Horiba will also introduce its patient-sideLAQUAtwin Ca-11C pocket meter, which measures blood ionised calcium levels fast and is currently on special offer until 30th June 2022.
To register, visit: https://register.gotowebinar.com/register/6274625209458361872
The company says the two main benefits of the liquid formulation are precise dosing and ease of administration.
Vetmedin oral solution comes with a kg-bodyweight calibrated syringe to make it easy to give the preferred dose of 0.25 mg/kg twice daily to the nearest 0.5 kg bodyweight.
The maximum syringe volume is for a 12 kg dog.
The solution has a sweet taste to make it palatable and Boehringer says it is also ideal for dogs that need dental work but require treatment for their heart disease before general anaesthesia.
These dogs might struggle to eat chewable tablets due to oral discomfort, so a liquid treatment might be a better option.
The company highlights the EPIC1 and PROTECT2 studies which showed that Vetmedin delays the onset of CHF for dogs in the asymptomatic stage of heart disease and improves both the quality and length of life for dogs with MVD and DCM.
Vetmedin oral solution comes as a 50 ml bottle (each bottle lasts a 5 kg dog approximately 30 days), doesn't need to be refrigerated, has an 8-week shelf life once opened, and a 2-year shelf life as packaged.
VetMedin oral solution is now available to order from wholesalers.
The Council of the Royal College of Veterinary Surgeons has approved a new Health Protocol, which formalises a more compassionate approach to veterinary surgeons with health problems.
The Protocol will allow - in appropriate circumstances - veterinary surgeons (and, from next year, registered veterinary nurses) who suffer from health concerns affecting their ability to practise safely, to have the matter dealt with confidentially, without going to a full public Disciplinary Committee hearing.
It will allow individuals to access appropriate support and help away from the public spotlight, while ensuring that they do not put animals or the public at risk.
According to independent legal advice sought by the College, such an approach is appropriate and necessary in order for the College to fulfil its regulatory responsibilities - similar systems exist within other regulators.
The draft Protocol was the subject of consultation amongst the profession and the public over summer. Proposed amendments to the RCVS Guide to Professional Conduct, to support the introduction of the Health Protocol, were also approved in the November meeting.
RCVS Head of Professional Conduct, Gordon Hockey said: "The Protocol encourages anyone coming into contact with veterinary surgeons - including other veterinary surgeons, veterinary nurses, members of practice staff, clients and healthcare professionals - who have concerns about a veterinary surgeon's health to report those concerns to the RCVS as soon as is reasonably practicable.
"Veterinary surgeons and veterinary nurses who are concerned about the health of a veterinary surgeon must also take steps to ensure that animals are not put at risk and that the interests of the public, including those of their colleagues, are protected."
New research from the USA, published in the Equine Veterinary Journal (EVJ), has shown that a toxin from the box elder tree is the likely cause of Seasonal Pasture Myopathy (SPM), the US equivalent of the European disease known as Atypical Myopathy (AM).
According to the British Equine Veterinary Association, preliminary comparisons of these results with cases of AM in Europe suggest that the European condition may be linked to similar trees which could have an important bearing on the future prevention of the disease in Europe.
Seasonal Pasture Myopathy is a highly fatal muscle disease in Midwestern USA and Eastern Canada. A similar disorder called Atypical Myopathy is becoming increasingly frequent in the UK and Northern Europe. Outbreaks of both diseases tend to be seasonal, with most cases occurring in the autumn. Horses that develop SPM and AM are usually kept in sparse pastures with an accumulation of dead leaves dead wood and trees in or around the pasture and are often not fed any supplementary hay or feed.
The research1 identified that seeds from box elder trees were consistently present in the autumn pastures of all 12 horses enrolled in the study. These horses were from 11 different farms and had all presented with the clinical signs of SPM, which include muscular weakness and stiffness, dark urine, periods of recumbency, colic-like signs and muscle trembling. The toxic amino acid hypoglycin A, which is known to cause acquired multiple acyl CoA dehydrogenase deficiency (MADD) was shown to be present in the box elder seeds and hypoglycin metabolites were identified in the serum or urine of all the horses. All but one of the cases proved fatal.
Professor Valberg DVM PhD of the Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, who instigated the study, said: "The fact that another acquired form of MADD in rats and humans is caused by hypoglycin A ingestion strengthens our conclusion that hypoglycin A is the likely toxic cause of SPM in horses. We are intending to conduct further studies to determine the factors that affect the highly variable hypoglycin A concentrations in box elder seeds."
Professor Valberg has established collaborative links with groups in Europe in order to investigate if a similar toxin is involved in European Atypical Myopathy. Working with Professor Vince Gerber and Dr Lucia Unger at the University of Bern, Professor Valberg has obtained seeds from a tree related to the Box Elder found on many pastures where Atypical Myopathy has occurred.
Professor Celia Marr, Editor of Equine Veterinary Journal said: "This is a really important step forwards. We don't yet know for sure that the cause of European disease, Atypical Myopathy, is the same as Seasonal Pasture Myopathy in the US. But the clinical signs and MADD aberrations are identical and both conditions have a high fatality rate. It remains to be seen whether this research will help European horses, but there is no doubt that it will allow American horse owners to prevent this devastating condition affecting their horses with immediate effect."
1 Seasonal Pasture Myopathy/Atypical Myopathy in North America associated with Ingestion of Hypoglycin A within Seeds of the Box Elder Tree Stephanie J Valberg DVM PhD1, Beatrice T Sponseller Dr. med. vet2, Adrian D Hegeman PhD3, Jennifer Earing PhD, Jeffery B. Bender DVM MS1, Krishona L Martinson PhD4, Steven E Patterson PhD5, Lawrence Sweetman PhD1
On top of that, over 25% of vets said they don't talk to their farmer clients about the disposal of empty pharmaceutical waste.
The survey also found that while veterinary surgeons are aware that both glass and shatterproof plastic vials are incinerated, over 65% of those questioned believed that glass vials were more environmentally friendly, when in fact, the company says its CLAS (Ceva Layered Anti Shatter) shatterproof plastic vials have 33% less impact on the environment from cradle to grave2.
Ceva is producing a range of support materials, including tailored social media and newsletter content, to help vets to raise awareness of their pharmaceutical waste disposal service and drive improvements across the industry.
Peter Keyte, ruminant business unit manager at Ceva Animal Health said: "As an industry we should be doing all that we can to improve our environmentally friendly credentials.
“Ceva will continue to invest in innovative eco-friendly technology for livestock injectables and pioneer improvements to help ensure best practice throughout the industry.”
For further information, or to request a pharmaceutical waste disposal service support pack, contact your local Ceva account manager or call 01494 781510.
Vet Futures has published the results of a survey of the profession in which only half of veterinary surgeons who graduated within the last eight years say their career has matched their expectations.
The online survey gathered views from 892 veterinary students (via the Association of Veterinary Students) and 1,973 veterinary surgeons who had graduated within the last eight years, during May and June this year.
Although 37% of graduates reported that their working lives had met their expectations, and a further 13% said it had exceeded them, this left 50% partly or wholly unsatisfied. Furthermore, 10% said they were considering leaving the profession entirely.
The RCVS and the BVA say the results should be a “wakeup call” to the profession.
Vets who have been qualified for five years or more were least optimistic about the future, rating their opportunities for career progression less positively than more recent graduates. They were also least likely to feel that their degree had prepared them for their current work. Meanwhile, only 34% of students felt that their degree was preparing them ‘very well’ for the work they wanted to do.
73% of students intended to work in the UK, with most aspiring to work in small animal/exotic or mixed practice, although one in 10 was as yet undecided. Of the students, 45% said they wanted to become practice owners or partners. Clearly the reality is proving less enticing, because only 25% graduates shared the same aspiration. In addition, nearly double the number of graduates said they wanted to work outside clinical practice (18%), compared to students.
When looking for a job, the three factors that both graduates and students agreed would have the greatest influence on their choice of career were intellectual satisfaction, location and a supportive environment.
This last requirement chimes with the fact that among the most popular suggestions for improvement to the veterinary degree were compulsory modules on managing stress, personal development and work-life balance, alongside more teaching of business and finance skills, and extra-mural studies (EMS) placements in a wider range of settings, such as industry.
BVA President, John Blackwell, said: “The drop off in career satisfaction for vets during this crucial first eight years in practice is something we can’t afford to ignore. It points to frustration over career development opportunities and dissatisfaction with support available in practice. For the veterinary profession to remain sustainable, and an attractive career choice for the best and brightest, we need to address these issues with some urgency.”
RCVS President, Dr Bradley Viner, said: “We clearly need to address the disconnect between expectation and reality for many recent graduates. Reviewing the educational foundation of the profession is a thread that runs through many of the proposed actions that will be outlined in the Vet Futures report due this autumn. The teaching and assessment of non-clinical skills – both as part of the undergraduate curriculum and within postgraduate education – will be important, as will be the promotion of non-clinical career pathways.”
The survey also covered issues such as students’ aspirations in terms of the type (size, ownership, sector) of practice in which they would like to work, and graduates’ future career plans. It also considers attitudes from both groups with respect to new technology.
The full research report “Voices from the future of the profession,” can be read at www.vetfutures.org.uk/resources.
The recommendation follows the analysis of data collected as part of the company's Talk About Laminitis disease awareness initiative, which has seen more than 47,000 horses tested for PPID since it was launched in 20121.
The data revealed that, regardless of presenting clinical signs, a horse aged 15-20 is three times more likely to have PPID compared to a horse under 10, and this risk increases with age. For example, a horse of 20-25 is six times more likely to have PPID compared to a horse under 10 and a horse that is 25-30 is 10 times more likely to have PPID.
Boehringer says that despite the high prevalence of PPID in the older horse population, the clinical signs of the disease are insidious in onset and owners may simply associate them with the ageing process.
One study demonstrated that in a single population of horses over the age of 15 only 1.6% of owners reported signs of PPID2. However, when the same group of horses were examined by a veterinary surgeon, 21% were found to have signs of the disease.
Dr Jo Ireland, veterinary surgeon at the University of Liverpool, said: "It is often difficult for owners to spot the signs of PPID as they frequently associate them with the ageing process. However, PPID is now the fifth most commonly diagnosed disease in horses in the UK3.
"We are therefore encouraging veterinary surgeons to routinely test horses over 15 years of age or those that are displaying signs of PPID with an ACTH test."
The 'Talk About Laminitis' disease awareness initiative runs from June until the end of October and aims to raise awareness of the underlying hormonal causes of laminitis – PPID and Equine Metabolic Syndrome (EMS). As part of the scheme, the laboratory fees for the blood test which detects PPID (the basal ACTH test) are free.
Redwings’ head of veterinary and care, senior veterinary surgeon Nicky Jarvis, said: "Any initiative that decreases the incidence of laminitis developing in an older equine is invaluable. Laminitis is an extremely distressing condition for both the horse and the owner and the long-term consequences can be devastating. Knowing the underlying cause is a huge help in tackling the disease and we would encourage anyone to take advantage of this offer and get their veteran checked out."
For further information about 'Talk About Laminitis', visit www.talkaboutlaminitis.co.uk or contact your local Boehringer Ingelheim account manager.
The BSAVA reports the highest ever attendance at Congress this year: 6,178 veterinary surgeons, nurses, practice managers and students, 6% cent higher than in 2011 (the last time the BSAVA hosted its own Congress).
According to the association, a significant number of international delegates attended this year with almost 60 countries represented - notably Scandinavia (186 delegates), Germany (56), the Netherlands (40) and the USA (31).
Other highlights included:
Outgoing BSAVA president Mark Johnston said the event was the highlight of his presidential year: "Last year we showed the world how well the BSAVA can organise a major veterinary congress. But what is pleasing is that the momentum we gained from hosting the World and European meetings has continued into this year.
"We had more delegates in 2013 than in the last purely BSAVA Congress two years ago and to accomplish that in these difficult financial times is a remarkable achievement."
Newly inducted BSAVA president Michael Day (top right) said he was looking forward to extending the international aspect of BSAVA. The Australian-born Professor who has lived in the UK for well over two decades said: "BSAVA has made huge contributions to veterinary practice in the UK, and already has a global reputation for Congress and publications - I believe we have such a wealth of resources and so I am convinced we have so much more to offer the world".
The Veterinary Marketing Association has announced details of a new award for public relations, open to veterinary practices and companies.
The VMA says this award is to recognise the value that media and public relations can add to the marketing mix. It will be awarded to the company or veterinary practice that has delivered the most innovative PR campaign during 2011, as judged by a panel of industry professionals.
Organiser Claire Edmunds said: "The VMA Awards has become a coveted event for those involved in the animal health industry to showcase their marketing achievements. A range of categories has evolved since the awards began over 20 years ago, for marketing, creative communication and new media campaigns. However, we felt that an award for PR was required to complete the marketing mix".
Jane Manning from award sponsor Splash Marketing & Communications said: "We felt it was time to give the opportunity for those involved in PR to obtain the recognition they deserve alongside their creative colleagues.
"An effective PR campaign can be a highly influential marketing tool, so it's great news that the VMA has added this new award category. We hope that companies and agencies serving the animal health sector will embrace this new opportunity to showcase their creativity and hard work".
The award is for the most innovative PR initiative published during the year. This can be a single 'one-off' event or article, or a sustained campaign over a given period. The winner and two highly commended entries will be awarded at the VMA Awards on Friday 9th March 2012 at Shakespeare's UnderGlobe Theatre, London.
Further information on the awards and ticket application forms are available at the VMA's website - http://www.vma.org.uk/ or by calling 0844 561 6157. The deadline for entries is Friday 27th January 2012.
Eurovet Animal Health has launched Thyforon Flavoured (levothyroxine sodium, POM-V), which replaces the company's canine hypothyroid treatment Forthyron.
Eurovet says that Thyforon Flavoured has the same clinical efficacy of Forthyron and veterinary surgeons won't need to make any dose adjustments when transitioning to the new product.
However, Thyforon Flavoured, with its palatable formulation, now offers the benefit of being voluntarily accepted by over 70 per cent of dogs in taste trials1. In addition there is a new 800 mcg formulation which gives more prescribing options, particularly for the treatment of large and giant breeds.Thyforon Flavoured comes as easy-break tablets to make dose adjustment straightforward, in an easy-to-dispense blister pack.
Thyforon Flavoured is available now - the person responsible for placing the practice drug order should just ask for Thyforon Flavoured when placing the next drug order and where appropriate, the practice management system should be updated to reflect the new name.
Reference1. Eurovet Animal Health Internal Study report, acceptance study, November 2011
Genitrix has announced the reformulation of Cerusolve, which cleans and deodorises the external ear canal of cats and dogs.
According to the company, the reformulation has enhanced Cerusolve's exfoliant and keratolyic properties and has given it a new fresh fragrance. Cerusolve ingredients now include:
Cerusolve is presented in a 100 ml bottle with a soft canula for application. It is priced at £5.65.
Genitrix Marketing Director Rob Watkins said: "Cerusolve has proved itself in practice as a gentle but effective ear cleaner in dogs and cats. The reformulation has given us the opportunity to increase the acidity of the product following a recent study which suggested that topical acidifying products could be therapeutically beneficial for cutaneous yeast infections.
"We believe the new ingredients will enhance the product and, to celebrate its arrival, we're offering practices the opportunity to buy five bottles of Cerusolve and get one free."
Further details are available from Genitrix on 01403 786345.
The UK's first online gastric ulcer risk assessment for horse owners has just been launched as part of the 2009 Gastric Ulcer Awareness Month (GUAM), organised by Merial Equine Health.
Merial has developed the risk online questionnaire to enable owners to evaluate their horse's risk of ulcers. By logging on to the website http://www.gastriculcerrisk.co.uk/, owners, trainers and riders can complete a form which then returns the results via email. Where an animal is considered to be at medium to high risk, owners will be advised to consult their veterinary practice.
The company's Dr Emma Batson said: "Since the first GUAM in 2007, significant progress has been made in developing awareness and understanding of equine gastric ulcer syndrome.
"However there is still more to do! Our goal is to move gastric ulcers further up the diagnostic process, such that the condition is an early consideration for all horses presented with the vague symptoms associated with ulceration. We know that due to the vague nature of the symptoms, many of horses are suspected of other ailments such as back and teeth problems, general poor performance, or behavioural issues prior to being diagnosed with ulcers.
"This new initiative has been developed through consultation with practising internal medicine specialists. We hope it will help to highlight more cases and encourage clients into the practice with horses that are at genuine risk of ulcers. Further diagnosis, treatment and management measures can then be considered in consultation with the client.
"The website also has a veterinary page so that follow up information and any gastroscopy results can be recorded by the vet. We hope that this feedback will help generate some valuable data for the industry."
To help you promote this initiative, Merial has produced an impactful poster for use in practice waiting rooms, along with educational literature. The poster will be available as a loose insert in various publications during April and May.
For those practices which require a referral scoping service, Merial can put you in touch with three specialist consultants; Rachael Conwell (North) Dr.Tim Brazil (Midlands/nationwide) and Richard Hepburn (South West) who each provide a mobile scoping clinic.
Merial is also promising support for the mobile scoping service for the five practices that direct the largest number of clients to http://www.gastriculcerrisk.co.uk/
A number of events are also taking place during the month for vets, trainers and horse owners, including the following CPD events:
GUAM is supported by BEVA and Dr Batson hopes that the 2009 initiatives will further boost awareness, understanding and diagnosis of this underrated condition.
Idexx Laboratories has launched a new renal function test, Idexx SDMA, which the company says can detect chronic kidney disease (CKD) in dogs or cats months or even years earlier than traditional methods.
The test is based on a new renal biomarker - symmetric dimethylarginine (SDMA) - and is the result of collaboration with a number of global experts.
Simon Wootton, UK CAG Marketing Manager at Idexx said: "The high sensitivity of this marker for detecting CKD will allow vets to diagnose the disease a lot sooner than has been previously possible. Identifying the disease earlier will give vets more time to intervene and prescribe an appropriate course of action."
The company says that the Idexx SDMA test can identify renal disease in dogs up to nine months earlier than previous methods, while in cats the detection time can be up to 17 months earlier.
Dr Martha Cannon, BA VetMB DSAM(fel) RCVS Recognised Specialist in Feline Medicine of the Oxford Cat Clinic, said: "The launch of SDMA testing is very exciting. It offers the prospect of identifying chronic kidney disease at an earlier stage, which should mean we can treat it more effectively and allow us to maintain cats in the asymptomatic phase. This can improve longevity, but more importantly could help maintain a better quality of life for longer.
"SDMA is also unaffected by muscle loss, which will allow us to assess the true extent of CKD in our elderly and underweight cats. This will lead to improved treatment choices, better quality of life and more peace of mind for owners."
The value of the new test has been validated by the adoption of SDMA into the International Renal Interest Society (IRIS) guidelines as a biomarker for the early detection of CKD.
Jonathan W. Ayers, President and Chief Executive Officer of Idexx Laboratories, said: "Idexx SDMA is a result of our commitment to lead the industry in sustained research investments that serve to advance veterinary medicine. It represents a significant achievement in veterinary diagnostics. Hospitals in the USA already using Idexx SDMA have told us that it has transformed the way renal disease is diagnosed and treated."
Idexx SDMA is available to UK and Ireland reference laboratory customers now. Further information is available at www.idexxsdma.com.
Video shows Sylvia Conway MRCVS, UK Medical Affairs Consultant at Idexx, talking about the new test (can also be viewed here).
In particular, the association says it is looking for people with expertise in the following areas:
VMG President Rich Casey (pictured right) said: “During the last two years alone, we have launched a new suite of ILM-accredited Award in Veterinary Leadership and Management (AVLM) qualifications, together with our evidence-based Leadership Standards Framework.
"We have also announced our intent to support the specific needs of our members more closely through our own congress and other initiatives, as well as helping to guide the wider veterinary profession through the challenges and opportunities that lie ahead.
“We’re proud of what we have achieved so far but we have much more to do.
'We are looking for several new directors with specific skills to help us offer the highest level of support we can to our members in 2023 and beyond.”
The deadline for applications is 3 October 2022.
https://vetmg.com/vmg-new-director-search
The webinar will be presented by veterinary behaviourist, Sarah Heath BVSc PgCertVE DipECAWBM(BM) CCAB FHEA FRCVS, RCVS and EBVS European Specialist in Behavioural Medicine.
It will cover how to take a cat friendly approach to the microchipping appointment to reduce feline stress and make the process easier for both pet owners and veterinary staff.
A consent-based care approach will be discussed, together with the importance of educating cat owners and veterinary professionals on how to handle cats to minimise feline stress.
The webinar will also advise on the use of adjunctive therapies, such as pheromones and nutraceuticals, as well as the strategic use of pre vet visit medication, and will be followed by a Q&A session.
Tammie O’Leary, commercial lead at identi, said: “The introduction of the new cat microchipping legislation will lead to an increased number of feline patients being seen by veterinary practices.
"Our cat microchipping legislation webinar will help provide cat friendly advice for veterinary professionals and will include hints and tips to make cat microchipping appointments as stress free as possible.”
To register for the webinar, email contact@identichip.co.uk or call 0330 9128077.
The 10 minute survey seeks to capture the current level of understanding and feelings around the deployment of AI tools across the veterinary industry.
VetCT says the purpose of the survey is to start some discussion and identify areas where training and support could help veterinary practitioners.
Julien Labruyère, Chief Innovation Officer at VetCT (pictured), said: “AI is here to stay and will increasingly become part of all aspects of veterinary medicine.
"Indeed, it’s vital to help us solve some of the workforce pressures the profession is facing globally.
"We will increasingly be using the outputs of AI tools to inform our clinical decisions, and yet the mechanisms and algorithms can be something of a black box of mystery.
“We want to understand the needs of clinicians in understanding how to apply AI safely, effectively and with confidence to support good clinical practice and ultimately, improve animal welfare.
"The results will be published and freely accessible.
"Our hope is to encourage a collaborative effort to support veterinary teams with embracing the full potential of AI, yet also providing the safeguards and education to the clinicians applying this technology to their patients.”
The survey is here: https://bit.ly/VetCT_AI_Survey.
Together, these two cancers account for almost a third of all canine cancers.
Dr. Heather Wilson-Robles, an Associate Professor at Texas A&M University and Chief Medical Officer of Volition Veterinary Diagnostics said: "The proof of concept results in these two very prevalent canine cancers give us confidence to move forward with other Nu.Q Vet assays in our pipeline, and with the larger range of cohorts and trials we have collected and planned.
"Clearly, we still have work to do as this single assay did not detect one of the other top five canine cancers, canine osteosarcoma, which was the third cancer tested in this study. However, I am delighted to see such positive results in these two significant cancers and look forward to reporting further data over the coming quarters with additional Nu.Q Vet assays, this time tested on an automated platform.”
Dr. Terry Kelly, Chief Scientific Officer of Volition America said: “It is exciting to see such strong results from our first Nu.Q Vet study conducted at Texas A&M University Veterinary Hospital. It is also interesting to note the similar patterns of detection seen in both canine and human samples confirming that the Nu.Q platform does appear to be useful in more than just human diagnostics.
"As with human diagnostics, there are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life. I look forward to completing the planned trials and to launch our first Nu.Q Vet product in the U.S. that we expect to occur in 2020."